Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 385 to 387 of 387 entries
Sorted by: Best Match Show Resources per page
Practitioners' views on the effects of the "For caring supervised visitation in child welfare" training.

Child abuse & neglect

Joly MP, Blais MF, Poirier MA, Gervais MJ, Soto Duran M.
PMID: 34217506
Child Abuse Negl. 2021 Jun 30;105167. doi: 10.1016/j.chiabu.2021.105167. Epub 2021 Jun 30.

BACKGROUND: In youth protection, the supervision of visits between children and their parent(s) with whom they no longer live is a complex clinical practice. The "For Caring Supervised Visitation in Child Welfare" training was designed to equip workers on...

Cite
Joly MP, Blais MF, Poirier MA, et al. Practitioners' views on the effects of the "For caring supervised visitation in child welfare" training. Child Abuse Negl. 2021;105167doi: 10.1016/j.chiabu.2021.105167.
Joly, M. P., Blais, M. F., Poirier, M. A., Gervais, M. J., & Soto Duran, M. (2021). Practitioners' views on the effects of the "For caring supervised visitation in child welfare" training. Child abuse & neglect, 105167. https://doi.org/10.1016/j.chiabu.2021.105167
Joly, Marie-Pierre, et al. "Practitioners' views on the effects of the "For caring supervised visitation in child welfare" training." Child abuse & neglect vol. (2021): 105167. doi: https://doi.org/10.1016/j.chiabu.2021.105167
Joly MP, Blais MF, Poirier MA, Gervais MJ, Soto Duran M. Practitioners' views on the effects of the "For caring supervised visitation in child welfare" training. Child Abuse Negl. 2021 Jun 30;105167. doi: 10.1016/j.chiabu.2021.105167. Epub 2021 Jun 30. PMID: 34217506.
Copy Download .nbib Format: NLM
First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50.

Future oncology (London, England)

Descourt R, Chouaid C, Pérol M, Besse B, Greillier L, Bylicki O, Ricordel C, Guisier F, Gervais R, Schott R, Auliac JB, Robinet G, Decroisette C.
PMID: 34156285
Future Oncol. 2021 Aug;17(23):3007-3016. doi: 10.2217/fon-2020-1202. Epub 2021 Jun 22.

Pembrolizumab plus chemotherapy is currently used in the first-line treatment of advanced non-small-cell lung cancer without

Cite
Descourt R, Chouaid C, Pérol M, et al. First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50. Future Oncol. 2021;17(23):3007-3016doi: 10.2217/fon-2020-1202.
Descourt, R., Chouaid, C., Pérol, M., Besse, B., Greillier, L., Bylicki, O., Ricordel, C., Guisier, F., Gervais, R., Schott, R., Auliac, J. B., Robinet, G., & Decroisette, C. (2021). First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50. Future oncology (London, England), 17(23), 3007-3016. https://doi.org/10.2217/fon-2020-1202
Descourt, Renaud, et al. "First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50." Future oncology (London, England) vol. 17,23 (2021): 3007-3016. doi: https://doi.org/10.2217/fon-2020-1202
Descourt R, Chouaid C, Pérol M, Besse B, Greillier L, Bylicki O, Ricordel C, Guisier F, Gervais R, Schott R, Auliac JB, Robinet G, Decroisette C. First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50. Future Oncol. 2021 Aug;17(23):3007-3016. doi: 10.2217/fon-2020-1202. Epub 2021 Jun 22. PMID: 34156285.
Copy Download .nbib Format: NLM
Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase.

Investigational new drugs

Modi T, Gervais D.
PMID: 34468906
Invest New Drugs. 2022 Feb;40(1):21-29. doi: 10.1007/s10637-021-01173-8. Epub 2021 Sep 01.

INTRODUCTION:  Erwinase® (native Erwinia chrysanthemi L-Asparaginase (nErA)) is an approved second-line treatment for acute lymphoblastic leukaemia (ALL) in children and adolescents, who develop hypersensitivity or neutralising antibodies to E.coli derived L-Asparaginases (ASNases). However, nErA has a short in vivo...

Cite
Modi T, Gervais D. Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase. Invest New Drugs. 2021;40(1):21-29doi: 10.1007/s10637-021-01173-8.
Modi, T., & Gervais, D. (2022). Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase. Investigational new drugs, 40(1), 21-29. https://doi.org/10.1007/s10637-021-01173-8
Modi, Tapasvi, and Gervais, David. "Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase." Investigational new drugs vol. 40,1 (2022): 21-29. doi: https://doi.org/10.1007/s10637-021-01173-8
Modi T, Gervais D. Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase. Invest New Drugs. 2022 Feb;40(1):21-29. doi: 10.1007/s10637-021-01173-8. Epub 2021 Sep 01. PMID: 34468906.
Copy Download .nbib Format: NLM
Showing 385 to 387 of 387 entries